Inhibition of lncExACT1 to treat heart disease
AssigneeThe General Hospital Corporation
InventorsAnthony Rosenzweig, Haobo Li
Life of this patent
Estimating the term…
Abstract
The disclosure provides compositions comprising an inhibitory nucleic acid targeting IncExACTI, and methods of use thereof to improve cardiac function in a subject in need thereof. Specifically, the disclosure provides a cardiac long noncoding RNA (IncRNA), referred as IncExACT 1 (SEQ ID NO: 1), and inhibitory nucleic acids targeting IncExACT 1 for reducing expression of IncExACT 1 and/or Dachsous cadherin-related 2 (DCHS2) in a cell, e.g., a cell in a subject for improving cardiac function in a subject, wherein the subject has pathological cardiac hypertrophy and/or heart failure.
Claims27
An inhibitory nucleic acid targeting IncExACTI (SEQ ID NO:1) that is 20 to 50 nucleotides in length, comprising a region of at least 20 consecutive nucleotides complementary to the IncExACTI, wherein the inhibitory nucleic acid is an antisense oligonucleotide or siRNA.
Dependencies are inferred from the claim text.